GlassScriptPhysician profile
Renato D Alberto
NPI 1245245109
$9,245.96
in general payments reported to CMS, 2019-2025
44 companies · $1,471 in 2025
The $1,471 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,405 · 2020: $1,221 · 2021: $1,597 · 2022: $1,486 · 2023: $712 · 2024: $1,355 · 2025: $1,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,537.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,619.24 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,439.22 | 2019-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $701.69 | 2021-2025 | |
| Amgen INC. | $613.43 | 2019-2025 | Repatha, Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $568.50 | 2019-2024 | Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $565.59 | 2019-2025 | Xifaxan |
| Mylan Specialty L.P. | $376.72 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $352.69 | 2019-2023 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $298.15 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $274.34 | 2019-2021 | |
| Daiichi Sankyo INC. | $220.01 | 2020-2022 | |
| Lilly USA, LLC | $201.12 | 2019-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $181.40 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $165.96 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $165.62 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renato Alberto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.